Gossamer Bio (GOSS) Research & Development (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Research & Development of $43.1 million for Q1 2026, up 13.23% year-over-year from $38.0 million in Q1 2025, and down 11.98% quarter-over-quarter from $48.9 million in Q4 2025.
Gossamer Bio (GOSS) Research & Development (2018 - 2026) Analysis & Trends
Gossamer Bio's Research & Development history runs 9 years deep, the most recent figure standing at $43.1 million for Q1 2026.
- In Q1 2026, Research & Development rose 13.23% year-over-year to $43.1 million; the TTM figure through Mar 2026 stood at $179.1 million (up 24.28% YoY), while the FY2025 annual figure was $174.1 million, up 25.71% from the prior year.
- Research & Development for Q1 2026 stood at $43.1 million, down from $48.9 million in the prior quarter.
- The five-year high for Research & Development was $48.9 million in Q4 2025, with the low at $30.0 million in Q4 2023.
- The 5-year median for Research & Development is $38.0 million (2025), against an average of $38.9 million.
- The sharpest annual moves came in 2023 and 2025: Research & Development slipped 29.9% in 2023, then soared 35.51% in 2025.
- Gossamer Bio's Research & Development stood at $41.5 million in 2022, then declined by 27.8% to $30.0 million in 2023, then rose by 20.49% to $36.1 million in 2024, then jumped by 35.51% to $48.9 million in 2025, then declined by 11.98% to $43.1 million in 2026.
- Business Quant data shows GOSS's Research & Development at $43.1 million in Q1 2026, $48.9 million in Q4 2025, and $45.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Gossamer Bio | 50.34 Mn | -6.69 Mn | - | 26.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.41 Mn |
| Mar 31, 2026 | 43.08 Mn |
| Dec 31, 2025 | 48.94 Mn |
| Sep 30, 2025 | 45.54 Mn |
| Jun 30, 2025 | 41.58 Mn |
| Mar 31, 2025 | 38.04 Mn |
| Dec 31, 2024 | 36.11 Mn |
| Sep 30, 2024 | 34.90 Mn |
| Jun 30, 2024 | 35.09 Mn |
| Mar 31, 2024 | 32.39 Mn |
| Dec 31, 2023 | 29.97 Mn |
| Sep 30, 2023 | 31.20 Mn |
| Jun 30, 2023 | 36.31 Mn |
| Mar 31, 2023 | 37.80 Mn |
| Dec 31, 2022 | 41.51 Mn |
| Sep 30, 2022 | 44.51 Mn |
| Jun 30, 2022 | 42.58 Mn |
| Mar 31, 2022 | 42.32 Mn |
| Dec 31, 2021 | 40.93 Mn |
| Sep 30, 2021 | 43.19 Mn |